Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

AstraZeneca buoyed as Imfinzi cuts lung cancer deaths by a third

AstraZeneca’s immunotherapy drug Imfinzi cut the risk of death in patients with mid-stage lung cancer by nearly a third in a closely watched clinical study, reinforcing the case for using the drug in earlier disease.

Read More »

AstraZeneca’s Diabetes Drug Farxiga Decreases Risk of Cardiovascular Disease

AstraZeneca announced positive results from the company’s Phase III DECLARE-TIMI 58 cardiovascular outcomes clinical trial of Farxiga (dapagliflozin).

Read More »

CDC: 14 Million Americans Will Have Alzheimer’s by 2060

Incidence of Alzheimer’s disease is projected to double in the next 40 years unless a cure or preventive measures are found.

Read More »

Viking shares surge after fatty liver drug trial

Viking Therapeutics Inc.’s shares more than doubled in value after promising data from a mid-stage trial of the company’s fatty liver drug were seen as topping that from larger rival Madrigal Pharmaceuticals.

Read More »

Cigna/Express Scripts deal gets antitrust nod

Health insurer Cigna Corp.’s $52 billion acquisition of pharmacy benefits manager Express Scripts Holding Co. passed U.S. antitrust scrutiny, the companies said.

Read More »

U.S. regulator approves Teva migraine drug, shares rise

Shares of Israeli drugmaker Teva Pharmaceutical Industries rose more than 5 percent after the U.S. Food and Drug Administration approved the company’s new migraine treatment.

Read More »

Bristol-Myers plaque psoriasis drug shows promise in mid-stage trial

Bristol-Myers Squibb’s experimental drug BMS-986165 helped reduce the severity of the most common form of psoriasis in a mid-stage trial.

Read More »

U.S. appeals court invalidates Acorda patents on MS drug

A U.S. appeals court invalidated Acorda Therapeutics Inc. patents covering the multiple sclerosis drug Ampyra, opening the door to generic competition for the company’s flagship product.

Read More »

ProQR childhood blindness drug succeeds in early study

An interim analysis of an early-stage trial showed that ProQR Therapeutics NV’s experimental treatment for a rare form of childhood blindness improved vision.

Read More »

Novartis says glaucoma stent setback will not derail Alcon spin-off

Novartis’ eye care unit Alcon is withdrawing a surgical stent for glaucoma patients after clinical data showed it may damage the eye, but the Swiss drugmaker said the move would not affect plans to spin off the unit 2019.

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

June 2019 Focus: Payer access, biotech/biopharma, DTC, rare diseases, and more!

Subscribe

Ad Right Bottom